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Group 1 2 (18%) 6 (55%) 11
Group 2 12 (34%) 25 (71%) 35
Group 3 74 (63%) 114 (97%) 117
Total 88 (54%) 145 (89%) 163
Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170 S161To prevent life-threatening encephalitis associated with
HHV-6 reactivation following SCT, we weekly examined
plasma HHV-6 DNA loads using real-time quantitative-po-
lymerase chain reaction methods until ﬁve weeks post-SCT
in 11 unrelated umbilical cord blood transplantation (CBT)
and 42 unmanipulated HLA-mismatched/haploidentical
related SCT (haplo-SCT).
CBT recipients were conditioned with cytarabine 12 g/m2,
cyclophosphamide 120 mg/kg, and total body irradiation
(TBI) 12 Gy as a myeloablative regimen and ﬂudarabine 200
mg/m2, cyclophosphamide 50 mg/kg, and TBI 3 Gy for a
reduced-intensity regimen. Prophylaxis for graft-versus-host
disease (GVHD) consisted of cyclosporine A, with myco-
phenolate mofetil (MMF) or a short course of methotrexate
(sMTX).
Haplo-SCT recipients were conditioned with ﬂudarabine
120 mg/m2, cytarabine 8 g/m2, cyclophosphamide 120
mg/kg, and TBI 8e12 Gy for a myeloablative regimen and
ﬂudarabine 180 mg/m2, rabbit ATG 8 mg/kg (Fresenius,
Munich, Germany) or 4 mg/kg (Genzyme, Tokyo, Japan), and
busulfan 8 mg/kg or melphalan for a reduced-intensity
regimen. Bone marrow and peripheral blood stem cells were
infused freshly without T-cell depletion. GVHD prophylaxis
against myeloablative and reduced-intensity haplo-SCT was
performed with tacrolimus, sMTX, MMF, and methylpred-
nisolone 2 mg/kg, and tacrolimus and methylprednisolone 1
mg/kg, respectively.
Compared to all of 11 CBT recipients (100%), plasma HHV-
6 DNA was detected in 3 of 42 haplo-SCT recipients (7.1%)
despite methylprednisolone use for graft-versus-host dis-
ease prophylaxis. As preemptive therapy, 8 CBT and 3 haplo-
SCT recipients were administered foscarnet or ganciclovir at
a median of four days (range, 0 to 9) after detection of HHV-6
DNA, followed by its rapid resolution except for one CBT
recipient who had repeatedly positive results. The remaining
3 CBT recipients were administered foscarnet before detec-
tion of plasma HHV-6 DNA. Despite HHV-6 reactivation, no
patients developed HHV-6-associated encephalitis.
In the present observations both HLA disparity, and the
use of methylprednisolone and antithymocyte globulin
was not necessarily a risk factor for development of HHV-6
reactivation in our haplo-SCT fashion. Furthermore,
preemptive or prophylactic administration of antivirals
potentially prevents HHV-6-associated encephalitis by
suppression of HHV-6 reactivation at an early stage of SCT.197
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Recent research suggests that beyond 8/8 allele level
matching at HLA-A, B, C, DRB1,matching at HLA-DPB1 should
be considered to improve patient survival rates in allogeneic
stem cell transplantation. DPB1 alleles have been separated
into three T-cell epitope (TCE) groups based on reactivity in
functional assays for matching: 1) high 2) intermediate 3)
low immunogenic potential. Non-permissive TCEmismatches at DPB1 are associated with a higher incidence
of transplant related mortality in patients that have a 10/10
matched donor.
We performed a study to identify the likelihood of having a
DPB1 permissive TCE matched donor for patients with 10/10
high resolution matched donor options (HapLogic predic-
tion of 75%) in the Be The Match Registry. 163 patient
searches from US transplant centers that submitted a pre-
liminary search request with DPB1 typing were evaluated for
DPB1 TCE permissive mismatched donors, either identiﬁed
through existing registry typing or by prospectively typing
up to 10 donors per patient.
88 of 163 patient searches had a DPB1 TCE permissive
mismatch present on the initial search results, 11 patient
searches did not have a potential DPB1 matched donor, and
the remaining 64 patient searches had up to 10 donors per
patient selected for DPB1 typing, prioritizing young male
donors. 57 out of 64 patients were able to ﬁnd a DPB1 TCE
permissive match via donor typing resulting in an overall
TCE permissive match rate of 89%. Table 1 shows the
condensed TCE groups of the patients assessed in the study,
with patients being classiﬁed by their highest immunogenic
TCE reactivity (i.e. 1>2>3). On initial donor search results,
patients carrying any DPB1 TCE group 1 allele found a match
18% of the time, 34% for group 2 and 63% for group 3. Typing
donors signiﬁcantly improved the identiﬁcation of a DPB1
permissive mismatched donor for all 3 groups to 55% for TCE
group 1, 71% group 2 and 97% for group 3.
This study selection process focused on patients with more
productive searches and shows that identifying a DPB1 TCE
permissive matched donor in these cases is likely for the
majority of patients. HLA typing donors who are predicted to
be 10/10 matches for HLA-DPB1 may provide a feasible
strategy for optimizing donor selection regardless of patient
TCE group.198
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Loss of heterozygosity (LOH) for certain HLA class I alleles
provides tumor cells with an efﬁcient mechanism to escape
the T cell immune response. Here we report a case of com-
plete class I LOH in a patient suffering from acute myeloid
leukemia, which was associated with an intriguing HLA-
typing procedure. The patient was diagnosed with AML FAB
M1 and further analysis revealed a nucleophosmin1 (NPM1)
mutation and normal male karyotype 46XY.
In February 2013 two independently collected EDTA blood
samples (S1 + S2) arrived at our lab for HLA testing. Primary
HLA class I and II typing was done for S1 with Sanger
